SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This study is intended to evaluate the ability of SENS-401 to prevent the ototoxicity induced
by cisplatin in subjects with a neoplastic disease. It is a multicenter, randomized,
controlled, two-arm, open-label efficacy and safety study in adults with neoplastic disease
requiring treatment with cisplatin as part of the chemotherapy protocol plan.